Introduction: Breast cancer is the most common cancer in the Iranian female population, and the incidence of the disease is rising. Early detection in association with staging or grading the tumor is the most effectiv...Introduction: Breast cancer is the most common cancer in the Iranian female population, and the incidence of the disease is rising. Early detection in association with staging or grading the tumor is the most effective method to increase survival rates. Studies have revealed that cortactin overexpression may play a role in the final stages of tumor progression and affects invasion and cellular motility. The aim of this study is to evaluate cortactin gene expression among Iranian female patients with breast cancer. Materials and Methods: Samples belonging to 70 breast cancer patients were randomly selected from the Imam Khomeini tumor bank. Normal and tumor tissues were prepared and stored at -80°C. Cortactin gene expression was evaluated by real-time PCR. Finally the data, along with demographic and clinical parameters, were analyzed using Prism 5.0 software, followed by t-test and ANOVA analysis. Results: Cortactin gene expression among tumor tissues increased 95.71% in comparison with normal tissues. A significant correlation between cortactin gene expression and lymph nodes’ involvement (P = 0.0077) and tumor stage (P = 0.0030) was observed. However, tumor grade (P = 0.8598), tumor size (P = 0.3058), and patient’s age (P = 0.4135) had no significant correlation with the gene’s expression level. Discussion: This study demonstrated that the cortactin gene’s overexpression in breast cancer may enhance lymph nodes’ involvement. This study also found that the gene’s expression was raised significantly in progressed stages of the cancer. Therefore, cortactin gene overexpression is an important factor indicating breast cells’ invasion. Conclusion: The cortactin gene’s expression level can be considered an accurate indicator for female breast cancer and also an appropriate biomarker for this cancer in clinical evaluations.展开更多
In sub-Saharan Africa, breast cancer (BC) constitutes a serious public health problem and the genetic basis of its development is remaining poorly understood. Although the SNPs at codon 72 of <em>TP</em>53...In sub-Saharan Africa, breast cancer (BC) constitutes a serious public health problem and the genetic basis of its development is remaining poorly understood. Although the SNPs at codon 72 of <em>TP</em>53 (rs1042522) and at the UTR of <em>SET</em>8 (rs16917496) have both been associated with BC development among Asian and European women, no published data has been reported within African population. We herein report on the impact of these polymorphisms on the risk of BC among Cameroonian women. Blood samples were collected from 111 breast cancer patients and 224 controls. DNA was extracted from each sample and PCR-RFLP was used to investigate the polymorphisms at SNPs rs1042522 of <em>TP</em>53 and rs16917496 of <em>SET</em>8. Association studies were performed according to ethno-linguistic groups and menopausal status. The minor allele “T” of <em>SET</em>8 gene revealed a protective effect in premenopausal women (OR, 0.327;95% CI 0.125 - 0.852) while the CT genotype of <em>SET</em>8 was associated with increased risk of BC (OR, 2.93;95% CI, 1.1 - 7.8). The minor “G” allele of <em>TP</em>53 gene was significantly associated (OR, 2.533;95% CI, 1.455 - 4.408) with increased disease risk in premenopausal women while the CG genotype was significantly associated (OR, 0.39;95% CI, 0.23 - 0.69) with decreased risk of BC. A synergistic genetic interaction at both loci for CC genotype of SET8 and CG genotype of <em>TP</em>53 was associated (OR, 0.46;95% CI, 0.24 - 0.91) with reduced disease risk. No significant association between polymorphisms at the SET8 and <em>TP</em>53 loci and clinical pathologic features of BC was observed. This study suggests significant associations between the SNPs located at the 3’-UTR of <em>SET</em>8 and codon 72 of the <em>TP</em>53 with the risk of breast cancer development among premenopausal women. There is an interaction between <em>TP</em>53 and <em>SET</em>8 genes.展开更多
目的总结非小细胞肺癌与肿瘤微环境领域的研究热点与趋势。方法检索Web of Science数据库中核心合集的数据,检索时限为2014年1月1日~2024年12月31日。运用Excle 2018版和CiteSpace 6.4.R1版软件,对纳入文献的发表年份、发表国家、期刊...目的总结非小细胞肺癌与肿瘤微环境领域的研究热点与趋势。方法检索Web of Science数据库中核心合集的数据,检索时限为2014年1月1日~2024年12月31日。运用Excle 2018版和CiteSpace 6.4.R1版软件,对纳入文献的发表年份、发表国家、期刊、作者、研究机构、关键词、文献共被引等进行文献计量学分析。结果共纳入2840篇文献,该领域发文量总体上升,引用频次也呈现逐年递增趋势。发文量最大的国家是中国,其次为美国和意大利;发文量最大的研究机构是法国国家医学与健康研究院;发文量最大,文献被引频次最高的作者是周彩存;发文量最大,被引频次最高的期刊分别是Frontiers in Immunology,Clinical Cancer Research。关键词共现分析展现出肿瘤微环境细胞成分、时空异质性与细胞外囊泡所介导的调控机制是研究热点。参考文献共被引分析形成了围绕单细胞测序、空间转录组、生物信息学分析为技术手段的肿瘤微环境研究,围绕kras、egfr突变、血管生成以及获得性耐药展开的肿瘤微环境相关基础研究,以及围绕免疫检查点抑制剂伊匹木单抗、帕博利珠单抗、新辅助化疗联合免疫治疗展开的肿瘤微环境临床相关研究。结论采用文献计量学方法可清晰直观地看出全球非小细胞肺癌与肿瘤微环境的研究热点和趋势。展开更多
[目的]从全球水平分析肺癌终生罹患风险和死亡风险。[方法]利用GLOBOCAN2022肺癌发病、死亡数据和联合国发布的人口和全死因数据,采用调整多原发癌的方法估计全球和不同地区肺癌终生罹患风险和死亡风险。[结果]全球肺癌终生罹患风险为3....[目的]从全球水平分析肺癌终生罹患风险和死亡风险。[方法]利用GLOBOCAN2022肺癌发病、死亡数据和联合国发布的人口和全死因数据,采用调整多原发癌的方法估计全球和不同地区肺癌终生罹患风险和死亡风险。[结果]全球肺癌终生罹患风险为3.59%[95%置信区间(confidence interval,CI):3.58%~3.59%],居不同癌种的第3位。终生罹患风险值存在明显的性别差异和地区差异,男性风险值为4.43%(95%CI:4.42%~4.44%),高于女性[2.71%(95%CI:2.70%~2.72%)],男女性别比为1.63∶1;全球不同人类发展指数(human development index,HDI)地区中,风险值随着HDI水平的升高而增加,超高HDI地区风险值为5.36%(95%CI:5.34%~5.37%),低HDI地区风险值为0.34%(95%CI:0.33%~0.34%);全球20个地区中,东亚地区终生罹患风险最高,为7.53%(95%CI:7.52%~7.55%);西非地区风险值最低,为0.16%(95%CI:0.16%~0.17%)。全球肺癌终生死亡风险为2.78%(95%CI:2.78%~2.78%),居不同癌种的第1位。终生死亡风险也存在明显的性别差异和地区差异,男性风险值[3.64%(95%CI:3.63%~3.64%)]高于女性[1.89%(95%CI:1.89%~1.90%)],男女性别比为1.93∶1;全球不同HDI水平地区中,风险值随着HDI水平的升高而增加,超高HDI地区风险值为3.98%(95%CI:3.97%~3.99%),低HDI地区风险值为0.31%(95%CI:0.31%~0.31%);全球20个地区中,死亡风险最高的为密克罗尼西亚联邦/波利尼西亚[5.80%(95%CI:4.98%~6.62%)],死亡风险最低的为西非[0.15%(95%CI:0.15%~0.16%)]。中国肺癌终生罹患风险和死亡风险分别为7.54%(95%CI:7.52%~7.56%)和5.88%(95%CI:5.87%~5.90%),均居所有癌种的第1位。[结论]全球和不同地区肺癌终生罹患风险和死亡风险仍然较高,风险值随着HDI水平的增加而升高,中国肺癌终生罹患风险和死亡风险均高于全球水平,提示基于肺癌相关危险因素和筛查与早诊早治的综合防控措施仍需不断加强,从而降低肺癌疾病负担。展开更多
文摘Introduction: Breast cancer is the most common cancer in the Iranian female population, and the incidence of the disease is rising. Early detection in association with staging or grading the tumor is the most effective method to increase survival rates. Studies have revealed that cortactin overexpression may play a role in the final stages of tumor progression and affects invasion and cellular motility. The aim of this study is to evaluate cortactin gene expression among Iranian female patients with breast cancer. Materials and Methods: Samples belonging to 70 breast cancer patients were randomly selected from the Imam Khomeini tumor bank. Normal and tumor tissues were prepared and stored at -80°C. Cortactin gene expression was evaluated by real-time PCR. Finally the data, along with demographic and clinical parameters, were analyzed using Prism 5.0 software, followed by t-test and ANOVA analysis. Results: Cortactin gene expression among tumor tissues increased 95.71% in comparison with normal tissues. A significant correlation between cortactin gene expression and lymph nodes’ involvement (P = 0.0077) and tumor stage (P = 0.0030) was observed. However, tumor grade (P = 0.8598), tumor size (P = 0.3058), and patient’s age (P = 0.4135) had no significant correlation with the gene’s expression level. Discussion: This study demonstrated that the cortactin gene’s overexpression in breast cancer may enhance lymph nodes’ involvement. This study also found that the gene’s expression was raised significantly in progressed stages of the cancer. Therefore, cortactin gene overexpression is an important factor indicating breast cells’ invasion. Conclusion: The cortactin gene’s expression level can be considered an accurate indicator for female breast cancer and also an appropriate biomarker for this cancer in clinical evaluations.
文摘In sub-Saharan Africa, breast cancer (BC) constitutes a serious public health problem and the genetic basis of its development is remaining poorly understood. Although the SNPs at codon 72 of <em>TP</em>53 (rs1042522) and at the UTR of <em>SET</em>8 (rs16917496) have both been associated with BC development among Asian and European women, no published data has been reported within African population. We herein report on the impact of these polymorphisms on the risk of BC among Cameroonian women. Blood samples were collected from 111 breast cancer patients and 224 controls. DNA was extracted from each sample and PCR-RFLP was used to investigate the polymorphisms at SNPs rs1042522 of <em>TP</em>53 and rs16917496 of <em>SET</em>8. Association studies were performed according to ethno-linguistic groups and menopausal status. The minor allele “T” of <em>SET</em>8 gene revealed a protective effect in premenopausal women (OR, 0.327;95% CI 0.125 - 0.852) while the CT genotype of <em>SET</em>8 was associated with increased risk of BC (OR, 2.93;95% CI, 1.1 - 7.8). The minor “G” allele of <em>TP</em>53 gene was significantly associated (OR, 2.533;95% CI, 1.455 - 4.408) with increased disease risk in premenopausal women while the CG genotype was significantly associated (OR, 0.39;95% CI, 0.23 - 0.69) with decreased risk of BC. A synergistic genetic interaction at both loci for CC genotype of SET8 and CG genotype of <em>TP</em>53 was associated (OR, 0.46;95% CI, 0.24 - 0.91) with reduced disease risk. No significant association between polymorphisms at the SET8 and <em>TP</em>53 loci and clinical pathologic features of BC was observed. This study suggests significant associations between the SNPs located at the 3’-UTR of <em>SET</em>8 and codon 72 of the <em>TP</em>53 with the risk of breast cancer development among premenopausal women. There is an interaction between <em>TP</em>53 and <em>SET</em>8 genes.
文摘目的总结非小细胞肺癌与肿瘤微环境领域的研究热点与趋势。方法检索Web of Science数据库中核心合集的数据,检索时限为2014年1月1日~2024年12月31日。运用Excle 2018版和CiteSpace 6.4.R1版软件,对纳入文献的发表年份、发表国家、期刊、作者、研究机构、关键词、文献共被引等进行文献计量学分析。结果共纳入2840篇文献,该领域发文量总体上升,引用频次也呈现逐年递增趋势。发文量最大的国家是中国,其次为美国和意大利;发文量最大的研究机构是法国国家医学与健康研究院;发文量最大,文献被引频次最高的作者是周彩存;发文量最大,被引频次最高的期刊分别是Frontiers in Immunology,Clinical Cancer Research。关键词共现分析展现出肿瘤微环境细胞成分、时空异质性与细胞外囊泡所介导的调控机制是研究热点。参考文献共被引分析形成了围绕单细胞测序、空间转录组、生物信息学分析为技术手段的肿瘤微环境研究,围绕kras、egfr突变、血管生成以及获得性耐药展开的肿瘤微环境相关基础研究,以及围绕免疫检查点抑制剂伊匹木单抗、帕博利珠单抗、新辅助化疗联合免疫治疗展开的肿瘤微环境临床相关研究。结论采用文献计量学方法可清晰直观地看出全球非小细胞肺癌与肿瘤微环境的研究热点和趋势。
文摘[目的]从全球水平分析肺癌终生罹患风险和死亡风险。[方法]利用GLOBOCAN2022肺癌发病、死亡数据和联合国发布的人口和全死因数据,采用调整多原发癌的方法估计全球和不同地区肺癌终生罹患风险和死亡风险。[结果]全球肺癌终生罹患风险为3.59%[95%置信区间(confidence interval,CI):3.58%~3.59%],居不同癌种的第3位。终生罹患风险值存在明显的性别差异和地区差异,男性风险值为4.43%(95%CI:4.42%~4.44%),高于女性[2.71%(95%CI:2.70%~2.72%)],男女性别比为1.63∶1;全球不同人类发展指数(human development index,HDI)地区中,风险值随着HDI水平的升高而增加,超高HDI地区风险值为5.36%(95%CI:5.34%~5.37%),低HDI地区风险值为0.34%(95%CI:0.33%~0.34%);全球20个地区中,东亚地区终生罹患风险最高,为7.53%(95%CI:7.52%~7.55%);西非地区风险值最低,为0.16%(95%CI:0.16%~0.17%)。全球肺癌终生死亡风险为2.78%(95%CI:2.78%~2.78%),居不同癌种的第1位。终生死亡风险也存在明显的性别差异和地区差异,男性风险值[3.64%(95%CI:3.63%~3.64%)]高于女性[1.89%(95%CI:1.89%~1.90%)],男女性别比为1.93∶1;全球不同HDI水平地区中,风险值随着HDI水平的升高而增加,超高HDI地区风险值为3.98%(95%CI:3.97%~3.99%),低HDI地区风险值为0.31%(95%CI:0.31%~0.31%);全球20个地区中,死亡风险最高的为密克罗尼西亚联邦/波利尼西亚[5.80%(95%CI:4.98%~6.62%)],死亡风险最低的为西非[0.15%(95%CI:0.15%~0.16%)]。中国肺癌终生罹患风险和死亡风险分别为7.54%(95%CI:7.52%~7.56%)和5.88%(95%CI:5.87%~5.90%),均居所有癌种的第1位。[结论]全球和不同地区肺癌终生罹患风险和死亡风险仍然较高,风险值随着HDI水平的增加而升高,中国肺癌终生罹患风险和死亡风险均高于全球水平,提示基于肺癌相关危险因素和筛查与早诊早治的综合防控措施仍需不断加强,从而降低肺癌疾病负担。
